ALLO Allogene Therapeutics Inc
Price (delayed)
$1.37
Market cap
$297.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.32
Enterprise value
$212.14M
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by
Highlights
Allogene Therapeutics's debt has plunged by 100% from the previous quarter
The EPS has grown by 37% YoY and by 15% from the previous quarter
ALLO's revenue has dropped by 77% year-on-year and by 49% since the previous quarter
The gross profit has dropped by 77% year-on-year and by 49% since the previous quarter
Key stats
What are the main financial stats of ALLO
Market
Valuations
Earnings
Shares outstanding
217.26M
Market cap
$297.65M
Enterprise value
$212.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.68
Price to sales (P/S)
12,131.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9,642.85
Revenue
$22,000
Gross profit
$22,000
Operating income
-$273.2M
Net income
-$257.59M
EBIT
-$256.97M
EBITDA
-$243.33M
Free cash flow
-$200.99M
Per share
Balance sheet
Liquidity
EPS
-$1.32
EPS diluted
-$1.32
Free cash flow per share
-$1.03
Book value per share
$2.01
Revenue per share
$0
TBVPS
$2.82
Total assets
$548.71M
Total liabilities
$126.53M
Debt
$0
Equity
$422.18M
Working capital
$267.86M
Debt to equity
0
Current ratio
8.54
Quick ratio
8.52
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
-1.11M%
Gross margin
100%
Net margin
-1.17M%
Operating margin
-1.24M%
Return on assets
-43.5%
Return on equity
-55.3%
Return on invested capital
-53.2%
Return on capital employed
-50.1%
Return on sales
-1.17M%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALLO stock price
How has the Allogene Therapeutics stock price performed over time
Intraday
-6.16%
1 week
-14.38%
1 month
-29.74%
1 year
-68.72%
YTD
-35.68%
QTD
-6.16%
Financial performance
How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$22,000
Gross profit
$22,000
Operating income
-$273.2M
Net income
-$257.59M
Gross margin
100%
Net margin
-1.17M%
The operating margin has dropped by 79% since the previous quarter
Allogene Therapeutics's net margin has plunged by 78% from the previous quarter
ALLO's revenue has dropped by 77% year-on-year and by 49% since the previous quarter
The gross profit has dropped by 77% year-on-year and by 49% since the previous quarter
Growth
What is Allogene Therapeutics's growth rate over time
Valuation
What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
0.68
P/S
12,131.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9,642.85
The EPS has grown by 37% YoY and by 15% from the previous quarter
ALLO's price to book (P/B) is 68% less than its 5-year quarterly average of 2.3 and 39% less than its last 4 quarters average of 1.2
Allogene Therapeutics's equity has decreased by 18% YoY and by 9% QoQ
The stock's price to sales (P/S) is 123% more than its 5-year quarterly average of 5796.5 and 8% more than its last 4 quarters average of 11996.1
ALLO's revenue has dropped by 77% year-on-year and by 49% since the previous quarter
Efficiency
How efficient is Allogene Therapeutics business performance
The ROS has plunged by 77% from the previous quarter
The return on assets has increased by 5% since the previous quarter and by 4.6% year-on-year
The return on equity has increased by 4.8% since the previous quarter and by 2.5% year-on-year
ALLO's return on invested capital is up by 5% since the previous quarter
Dividends
What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALLO.
Financial health
How did Allogene Therapeutics financials performed over time
ALLO's current ratio is down by 31% YoY and by 9% from the previous quarter
ALLO's quick ratio is down by 31% year-on-year and by 8% since the previous quarter
Allogene Therapeutics's debt is 100% less than its equity
The company's debt to equity has shrunk by 100% QoQ
Allogene Therapeutics's debt has plunged by 100% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.